FDA Approved New Treatment for Nephrotic Syndrome
Children and adults aged 2 and older with relapsing or steroid-dependent kidney disease may now access Gazyva.
Updated on Sept. 25, 2026 in Cancer
Live Poll
Do you trust the FDA's current process for approving new medical treatments?
The FDA approved Gazyva for the treatment of idiopathic nephrotic syndrome in patients aged 2 years and older who are in remission. This kidney disorder, which has an estimated annual incidence of 1 to 4 per 100,000 children, now has a new option for those requiring ongoing management.
Why it matters
This approval provides a new therapeutic pathway for patients struggling with frequently relapsing or steroid-dependent forms of this complex kidney condition. It allows physicians to consider an alternative treatment approach for patients who have already achieved remission.
In the Phase 3 INSHORE study of 85 patients, Gazyva demonstrated efficacy in maintaining remission. The trial assessed the proportion of patients achieving a urine protein-creatinine ratio of 0.2 g/g or less at Week 52.
The players
FDA
The federal agency responsible for regulating pharmaceuticals, medical devices, and public health safety in the United States.
Gazyva
An intravenous therapy previously approved for certain cancers and active lupus nephritis.
The details
Gazyva is administered via intravenous injection on a schedule of Days 1 and 15, followed by infusions at Weeks 24 and 26. The therapy requires that patients are already in remission before starting the drug to manage the underlying protein-leaking kidney disorder. The label includes boxed warnings regarding the risk of hepatitis B virus reactivation and progressive multifocal leukoencephalopathy, while common side effects include neutropenia, infections, and infusion-related reactions.
Timeline
September 25, 2026: FDA approved Gazyva for idiopathic nephrotic syndrome.
Week 52: Assessment of the primary protein-creatinine ratio endpoint.
Health Landscape
This development represents an expansion of Gazyva's clinical application from oncology and lupus nephritis into the management of idiopathic nephrotic syndrome. It aligns with the trend of repurposing established monoclonal antibody therapies to address rare, complex renal conditions.
Patients and families affected by steroid-dependent nephrotic syndrome should speak with their nephrologist to discuss whether this therapy is an appropriate consideration for their care plan. Given the specific boxed warnings, it is vital to review your medical history and potential risks with your clinical team.
The takeaway
This approval offers a new intravenous option for patients who struggle with recurring or steroid-dependent kidney protein leakage. Patients should consult their primary nephrologist to determine if this therapy is a safe and suitable addition to their existing treatment regimen.
Further reading
For more information on the latest developments in systemic therapies, visit the Cancer section.
More information
Review the full FDA drug approval press release for detailed clinical context.
Live Poll
Do you trust the FDA's current process for approving new medical treatments?
